PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
In classical Hodgkin lymphoma (cHL)—characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells—tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs a...
Saved in:
Published in | Leukemia Vol. 34; no. 9; pp. 2405 - 2417 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.09.2020
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In classical Hodgkin lymphoma (cHL)—characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells—tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs are known to express PD-L1, which leads to PD-1
+
CD4
+
T cell exhaustion in cHL. Here, we found that PD-L1/L2 expression was elevated in monocytes co-cultured with HRS cells within 1 h, but not in monocytes cultured with supernatants of HRS cells. Immunofluorescence analysis of PD-L1/L2 revealed that their upregulation resulted in membrane transfer called “trogocytosis” from HRS cells to monocytes. PD-L1/L2 upregulation was not observed in monocytes co-cultured with PD-L1/L2-deficient HRS cells, validating the hypothesis that there is a direct transfer of PD-L1/L2 from HRS cells to monocytes. In the patients, both ligands (PD-L1/L2) were upregulated in TAMs in contact with HRS cells, but not in TAMs distant from HRS cells, suggesting that trogocytosis occurs in cHL patients. Taken together, trogocytosis may be one of the mechanisms that induces rapid upregulation of PD-L1/L2 in monocytes to evade antitumor immunity through the suppression of T cells as mediated by MHC antigen presentation. |
---|---|
AbstractList | In classical Hodgkin lymphoma (cHL)--characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells--tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs are known to express PD-L1, which leads to PD-1.sup.+ CD4.sup.+ T cell exhaustion in cHL. Here, we found that PD-L1/L2 expression was elevated in monocytes co-cultured with HRS cells within 1 h, but not in monocytes cultured with supernatants of HRS cells. Immunofluorescence analysis of PD-L1/L2 revealed that their upregulation resulted in membrane transfer called "trogocytosis" from HRS cells to monocytes. PD-L1/L2 upregulation was not observed in monocytes co-cultured with PD-L1/L2-deficient HRS cells, validating the hypothesis that there is a direct transfer of PD-L1/L2 from HRS cells to monocytes. In the patients, both ligands (PD-L1/L2) were upregulated in TAMs in contact with HRS cells, but not in TAMs distant from HRS cells, suggesting that trogocytosis occurs in cHL patients. Taken together, trogocytosis may be one of the mechanisms that induces rapid upregulation of PD-L1/L2 in monocytes to evade antitumor immunity through the suppression of T cells as mediated by MHC antigen presentation. In classical Hodgkin lymphoma (cHL)—characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells—tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs are known to express PD-L1, which leads to PD-1 + CD4 + T cell exhaustion in cHL. Here, we found that PD-L1/L2 expression was elevated in monocytes co-cultured with HRS cells within 1 h, but not in monocytes cultured with supernatants of HRS cells. Immunofluorescence analysis of PD-L1/L2 revealed that their upregulation resulted in membrane transfer called “trogocytosis” from HRS cells to monocytes. PD-L1/L2 upregulation was not observed in monocytes co-cultured with PD-L1/L2-deficient HRS cells, validating the hypothesis that there is a direct transfer of PD-L1/L2 from HRS cells to monocytes. In the patients, both ligands (PD-L1/L2) were upregulated in TAMs in contact with HRS cells, but not in TAMs distant from HRS cells, suggesting that trogocytosis occurs in cHL patients. Taken together, trogocytosis may be one of the mechanisms that induces rapid upregulation of PD-L1/L2 in monocytes to evade antitumor immunity through the suppression of T cells as mediated by MHC antigen presentation. In classical Hodgkin lymphoma (cHL)—characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells—tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs are known to express PD-L1, which leads to PD-1+ CD4+ T cell exhaustion in cHL. Here, we found that PD-L1/L2 expression was elevated in monocytes co-cultured with HRS cells within 1 h, but not in monocytes cultured with supernatants of HRS cells. Immunofluorescence analysis of PD-L1/L2 revealed that their upregulation resulted in membrane transfer called “trogocytosis” from HRS cells to monocytes. PD-L1/L2 upregulation was not observed in monocytes co-cultured with PD-L1/L2-deficient HRS cells, validating the hypothesis that there is a direct transfer of PD-L1/L2 from HRS cells to monocytes. In the patients, both ligands (PD-L1/L2) were upregulated in TAMs in contact with HRS cells, but not in TAMs distant from HRS cells, suggesting that trogocytosis occurs in cHL patients. Taken together, trogocytosis may be one of the mechanisms that induces rapid upregulation of PD-L1/L2 in monocytes to evade antitumor immunity through the suppression of T cells as mediated by MHC antigen presentation. In classical Hodgkin lymphoma (cHL)-characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells-tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs are known to express PD-L1, which leads to PD-1 CD4 T cell exhaustion in cHL. Here, we found that PD-L1/L2 expression was elevated in monocytes co-cultured with HRS cells within 1 h, but not in monocytes cultured with supernatants of HRS cells. Immunofluorescence analysis of PD-L1/L2 revealed that their upregulation resulted in membrane transfer called "trogocytosis" from HRS cells to monocytes. PD-L1/L2 upregulation was not observed in monocytes co-cultured with PD-L1/L2-deficient HRS cells, validating the hypothesis that there is a direct transfer of PD-L1/L2 from HRS cells to monocytes. In the patients, both ligands (PD-L1/L2) were upregulated in TAMs in contact with HRS cells, but not in TAMs distant from HRS cells, suggesting that trogocytosis occurs in cHL patients. Taken together, trogocytosis may be one of the mechanisms that induces rapid upregulation of PD-L1/L2 in monocytes to evade antitumor immunity through the suppression of T cells as mediated by MHC antigen presentation. |
Audience | Academic |
Author | Hoshina, Takahiro Carreras, Joaquim Higuchi, Hiroshi Kitamura, Toshio Kakizaki, Masatoshi Miyatake, Yuji Nakamura, Naoya Katagiri, Koko Goyama, Susumu Higuchi, Yuriko Kotani, Ai Yano, Shingo Kawashima, Masaharu Kotaki, Ryutaro Chamoto, Kenji Ando, Kiyoshi Okuyama, Kazuki Suzuki, Naoto Nakayama, Masafumi Umezu, Shinjiro Horie, Ryouichi |
Author_xml | – sequence: 1 givenname: Masaharu surname: Kawashima fullname: Kawashima, Masaharu organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Division of Clinical Oncology and Hematology, Jikei University School of Medicine – sequence: 2 givenname: Joaquim surname: Carreras fullname: Carreras, Joaquim organization: Department of Pathology, Tokai University School of Medicine – sequence: 3 givenname: Hiroshi surname: Higuchi fullname: Higuchi, Hiroshi organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Research Institute of Science and Technology, Tokai University – sequence: 4 givenname: Ryutaro surname: Kotaki fullname: Kotaki, Ryutaro organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University – sequence: 5 givenname: Takahiro surname: Hoshina fullname: Hoshina, Takahiro organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo – sequence: 6 givenname: Kazuki surname: Okuyama fullname: Okuyama, Kazuki organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University – sequence: 7 givenname: Naoto surname: Suzuki fullname: Suzuki, Naoto organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Department of Biosciences, School of Science, Kitasato University, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo – sequence: 8 givenname: Masatoshi surname: Kakizaki fullname: Kakizaki, Masatoshi organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University – sequence: 9 givenname: Yuji surname: Miyatake fullname: Miyatake, Yuji organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University – sequence: 10 givenname: Kiyoshi surname: Ando fullname: Ando, Kiyoshi organization: Department of Hematology and Oncology, Tokai University School of Medicine – sequence: 11 givenname: Masafumi surname: Nakayama fullname: Nakayama, Masafumi organization: Frontier Research Institute for Interdisciplinary Sciences, Tohoku University – sequence: 12 givenname: Shinjiro surname: Umezu fullname: Umezu, Shinjiro organization: Department of Modern Mechanical Engineering, Waseda University – sequence: 13 givenname: Ryouichi surname: Horie fullname: Horie, Ryouichi organization: Division of Hematology, Department of Laboratory Sciences, School of Allied Health Sciences, Kitasato University – sequence: 14 givenname: Yuriko surname: Higuchi fullname: Higuchi, Yuriko organization: Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University – sequence: 15 givenname: Koko surname: Katagiri fullname: Katagiri, Koko organization: Department of Biosciences, School of Science, Kitasato University – sequence: 16 givenname: Susumu surname: Goyama fullname: Goyama, Susumu organization: Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo – sequence: 17 givenname: Toshio surname: Kitamura fullname: Kitamura, Toshio organization: Division of Cellular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo – sequence: 18 givenname: Kenji surname: Chamoto fullname: Chamoto, Kenji organization: Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University – sequence: 19 givenname: Shingo surname: Yano fullname: Yano, Shingo organization: Division of Clinical Oncology and Hematology, Jikei University School of Medicine – sequence: 20 givenname: Naoya surname: Nakamura fullname: Nakamura, Naoya organization: Department of Pathology, Tokai University School of Medicine – sequence: 21 givenname: Ai surname: Kotani fullname: Kotani, Ai email: aikotani@k-lab.jp organization: Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, AMED-PRIME, Japan Agency for Medical Research and Development |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32089543$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kl1rFDEUhoNU7Lb6A7yRgCC9mTZfk4_L0morLOiFXodMktlNnUnWZKaw_94MW60VlUBCcp735JzkPQFHMUUPwGuMzjGi8qIwTEXbIIIaJKho1DOwwkzwpm1bfARWSErRcEXYMTgp5Q6hJchfgGNKkFQtoyswf75u1vhiTeAup8mHCAd_74cCs9kFN-xhiDZ7UzxMEY4pJruffIH3wcApp82yTSUU2Oc0wmkeU4bWD1VfM9nBlBKsGeBtcptvS-79uNum0bwEz3szFP_qYT0FXz-8_3J126w_3Xy8ulw3lis-NY5jLlyn-t47wWzHqGtdK61ErrbGWU-dbFHfkk54LhRz9RG8kqqTPSUKSXoKzg55a3PfZ18mPYay1GeiT3PRhHKKBCKEVfTtH-hdmnOs1WnCRIuwrPP_KSqIkFiKR2pjBq9D7NOUjV2u1pecUs4ZIUtx53-h6nB-DLb-dB_q-RPBu98EW2-GaVvSME8hxfIUxAfQ5lRK9r3e5TCavNcY6cU5-uAcXZ2jF-doVTVvHjqbu9G7X4qfVqkAOQClhuLG58fW_531Bwz7zMA |
CitedBy_id | crossref_primary_10_3389_fonc_2023_1203470 crossref_primary_10_1126_sciadv_abj3286 crossref_primary_10_3960_jslrt_21005 crossref_primary_10_3390_cancers14112647 crossref_primary_10_3390_cancers14102427 crossref_primary_10_1016_j_isci_2022_105110 crossref_primary_10_1016_j_intimp_2022_109235 crossref_primary_10_3389_fimmu_2020_01109 crossref_primary_10_1080_10428194_2021_2023744 crossref_primary_10_3390_biomedicines10071587 crossref_primary_10_1016_j_humpath_2022_12_014 crossref_primary_10_3390_cancers13174357 crossref_primary_10_3324_haematol_2022_280014 crossref_primary_10_3390_cancers12082286 crossref_primary_10_3960_jslrt_21034 crossref_primary_10_3390_cancers13143634 crossref_primary_10_1080_2162402X_2020_1781334 crossref_primary_10_1111_bjh_17282 crossref_primary_10_3389_fimmu_2023_1160340 crossref_primary_10_1016_j_jare_2024_01_013 crossref_primary_10_3389_fimmu_2022_791006 crossref_primary_10_1016_j_humimm_2022_08_013 crossref_primary_10_3389_fonc_2023_1149616 crossref_primary_10_1038_s41392_023_01708_w crossref_primary_10_3390_ijms22052236 crossref_primary_10_1097_PAS_0000000000002062 crossref_primary_10_1007_s12308_023_00530_1 crossref_primary_10_3390_cancers15041085 crossref_primary_10_3389_fimmu_2024_1397005 crossref_primary_10_1038_s41375_021_01204_6 |
Cites_doi | 10.1016/j.celrep.2017.04.031 10.1189/jlb.3MR0315-136R 10.1182/blood-2002-01-0099 10.1158/1078-0432.CCR-14-1845 10.1016/j.humpath.2017.10.029 10.1038/cmi.2011.62 10.1182/blood-2007-05-085159 10.1073/pnas.1110584108 10.1172/JCI61245 10.1158/2326-6066.CIR-17-0325 10.1038/nature14426 10.1172/JCI96113 10.1182/blood-2007-09-112128 10.1182/blood-2010-05-282780 10.1056/NEJMoa0905680 10.1200/JCO.2017.77.3994 10.1158/1078-0432.CCR-13-0855 10.1038/cmi.2008.32 10.1182/blood-2014-11-610436 10.1038/nm.3773 10.1200/JCO.2010.32.8401 10.1200/JCO.2016.66.4482 10.1016/j.mayocp.2015.03.025 10.1038/ni0503-399 10.1038/cgt.2016.19 10.1038/nri2020 10.1096/fj.06-7488rev 10.1200/JCO.2016.72.1316 10.1038/nature13954 10.1016/S1470-2045(16)30167-X 10.1182/blood-2016-11-749556 10.1182/blood-2017-07-796342 10.1038/nature19330 10.1002/path.2711 10.1111/ejh.13033 10.3324/haematol.2011.050138 10.1056/NEJMoa1411087 10.1084/jem.20082173 10.1158/1078-0432.CCR-16-1761 10.1038/nature22991 10.1182/blood-2018-04-843714 10.1111/cas.13424 10.1182/blood-2012-04-421057 10.1182/blood-2017-03-770719 10.1007/s11912-017-0634-1 10.1200/JCO.2016.67.3467 10.3324/haematol.2018.196725 10.1146/annurev.immunol.26.021607.090331 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to Springer Nature Limited 2020 COPYRIGHT 2020 Nature Publishing Group The Author(s), under exclusive licence to Springer Nature Limited 2020. |
Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Limited 2020 – notice: COPYRIGHT 2020 Nature Publishing Group – notice: The Author(s), under exclusive licence to Springer Nature Limited 2020. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7RV 7T5 7T7 7TM 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7N M7P NAPCQ P64 PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1038/s41375-020-0737-9 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) ProQuest Nursing and Allied Health Journals Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Complete (ProQuest Database) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (ProQuest Medical & Health Databases) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Central Student MEDLINE ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1476-5551 |
EndPage | 2417 |
ExternalDocumentID | A633664228 10_1038_s41375_020_0737_9 32089543 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Research Program on Hepatitis from the Japan Agency for Medical Research and Development (Graduate Reference Number: 19fk0210054s0201) – fundername: MEXT | JST | Core Research for Evolutional Science and Technology (CREST) funderid: https://doi.org/10.13039/501100003382 – fundername: MEXT | JST | Precursory Research for Embryonic Science and Technology (PRESTO) grantid: AMED-PRIME funderid: https://doi.org/10.13039/501100009023 – fundername: The Jikei University Research Fund for Graduate Students – fundername: Uehara Memorial Foundation funderid: https://doi.org/10.13039/100008732 – fundername: MEXT | JST | Precursory Research for Embryonic Science and Technology (PRESTO) grantid: AMED-PRIME |
GroupedDBID | --- -Q- .55 .XZ 0R~ 29L 2WC 36B 39C 3V. 4.4 406 53G 5GY 5RE 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AAQQT AASDW AASML AATNV AAWBL AAWTL AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACZOJ ADBBV ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFFNX AFKRA AFRAH AFSHS AGAYW AGEZK AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EBC EBD EBLON EBS EBX EE. EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IH2 IHR IHW INH INR ITC IWAJR JSO JZLTJ KQ8 LGEZI LOTEE M1P M7P N9A NADUK NAO NAPCQ NQJWS NXXTH O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP WOW X7M Y6R ZGI ZXP ~8M AAYZH CGR CUY CVF ECM EIF NPM AAYXX CITATION AADWK AAYFA AAYJO ABGIJ ACBMV ACBRV ACBYP ACIGE ACTTH ACVWB ADMDM ADQMX ADYYL AEDAW AEFTE AFNRJ AGGBP AHGBK AJCLW AJDOV AMRJV NYICJ ZA5 7QL 7T5 7T7 7TM 7TO 7U9 7XB 8FD 8FE 8FH 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c696t-d6167db9ffed74cb43d5d58c80d08864f3d850f52b7e6794d737e989b8f329083 |
IEDL.DBID | BENPR |
ISSN | 0887-6924 |
IngestDate | Fri Oct 25 09:35:55 EDT 2024 Fri Oct 25 06:47:23 EDT 2024 Thu Oct 10 22:21:38 EDT 2024 Thu Feb 22 23:28:10 EST 2024 Fri Feb 02 04:23:48 EST 2024 Tue Aug 20 22:08:33 EDT 2024 Fri Aug 23 03:20:32 EDT 2024 Wed Oct 16 00:45:10 EDT 2024 Fri Oct 11 20:51:17 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c696t-d6167db9ffed74cb43d5d58c80d08864f3d850f52b7e6794d737e989b8f329083 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 32089543 |
PQID | 2437278187 |
PQPubID | 30521 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2363070224 proquest_journals_2475018475 proquest_journals_2437278187 gale_infotracmisc_A633664228 gale_infotracacademiconefile_A633664228 gale_healthsolutions_A633664228 crossref_primary_10_1038_s41375_020_0737_9 pubmed_primary_32089543 springer_journals_10_1038_s41375_020_0737_9 |
PublicationCentury | 2000 |
PublicationDate | 2020-09-01 |
PublicationDateYYYYMMDD | 2020-09-01 |
PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Leukemia |
PublicationTitleAbbrev | Leukemia |
PublicationTitleAlternate | Leukemia |
PublicationYear | 2020 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | KreiterSVormehrMvan de RoemerNDikenMLowerMDiekmannJMutant MHC class II epitopes drive therapeutic immune responses to cancerNature201552069261:CAS:528:DC%2BC2MXnsVWqt7c%3D259016824838069 CasagrandeNBorgheseCVisserLMongiatMColombattiAAldinucciDCCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growthHaematologica2019104564751:CAS:528:DC%2BC1MXhsVOqurbO303098536395337 AnsellSMLesokhinAMBorrelloIHalwaniAScottECGutierrezMPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN. Engl J Med2015372311925482239 ImSJHashimotoMGernerMYLeeJKissickHTBurgerMCDefining CD8+ T cells that provide the proliferative burst after PD-1 therapyNature2016537417211:CAS:528:DC%2BC28XhsFajsrzE275012485297183 TanKLScottDWHongFKahlBSFisherRIBartlettNLTumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialBlood2012120328071:CAS:528:DC%2BC38Xhs1eisLnO229480493476539 YounesASantoroAShippMZinzaniPLTimmermanJMAnsellSNivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialLancet Oncol2016171283941:CAS:528:DC%2BC28Xht1agtbvF274513905541855 SteidlCConnorsJMGascoyneRDMolecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironmentJ Clin Oncol2011291812261:CAS:528:DC%2BC3MXotFWmt7k%3D21483001 NakayamaMTakedaKKawanoMTakaiTIshiiNOgasawaraKNatural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4+ T cellsProc Natl Acad Sci USA20111081836051:CAS:528:DC%2BC3MXhsF2itrvO220428513215013 AhmedKAMunegowdaMAXieYXiangJIntercellular trogocytosis plays an important role in modulation of immune responsesCell Mol Immunol2008526191:CAS:528:DC%2BD1cXhtFylt7nN187618134651296 KuangDMZhaoQPengCXuJZhangJPWuCActivated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1J Exp Med20092061327371:CAS:528:DC%2BD1MXntFGmu7k%3D194512662715058 TumehPCHarviewCLYearleyJHShintakuIPTaylorEJRobertLPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature2014515568711:CAS:528:DC%2BC2cXitFanu7jL254285054246418 VariFArponDKeaneCHertzbergMSTalaulikarDJainSImmune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCLBlood20181311809191:CAS:528:DC%2BC1cXhvVemt7vK294492765922274 NakayamaMAntigen presentation by MHC-dressed cellsFront Immunol2014567225601867 GuPGaoJFD’SouzaCAKowalczykAChouKYZhangLTrogocytosis of CD80 and CD86 by induced regulatory T cellsCell Mol Immunol20129136461:CAS:528:DC%2BC38XjtlGrs74%3D223070404002813 LinnemannCvan BuurenMMBiesLVerdegaalEMSchotteRCalisJJHigh-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanomaNat Med20152181851:CAS:528:DC%2BC2cXitFKltLfJ25531942 ThornMGuhaPCunettaMEspatNJMillerGJunghansRPTumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastasesCancer Gene Ther201623188981:CAS:528:DC%2BC28Xot12gurg%3D27199222 YamamotoRNishikoriMKitawakiTSakaiTHishizawaMTashimaMPD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphomaBlood2008111322041:CAS:528:DC%2BD1cXjvVamurw%3D18203952 SkinniderBFThe role of cytokines in classical Hodgkin lymphomaBlood2002994283971:CAS:528:DC%2BD38XksFGlu74%3D12036854 von TresckowBMorschhauserFRibragVToppMSChienCSeetharamSAn open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphomaClin Cancer Res201521184350 KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol2008266777041:CAS:528:DC%2BD1cXltlWktrY%3D18173375 PorrataLFRistowKColganJPHabermannTMWitzigTEInwardsDJPeripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphomaHaematologica2012972629219936833269488 TadmorTBariAMarcheselliLSacchiSAvivABaldiniLAbsolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: evaluation based on data from 1450 patientsMayo Clin Proc2015907566426046410 SteidlCLeeTShahSPFarinhaPHanGNayarTTumor-associated macrophages and survival in classic Hodgkin’s lymphomaN. Engl J Med2010362875851:CAS:528:DC%2BC3cXjt1yls7Y%3D202201822897174 PanjwaniPKCharuVDeLisserMMolina-KirschHNatkunamYZhaoSProgrammed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypesHum Pathol20187191991:CAS:528:DC%2BC2sXhvFejsLvK29122656 GuoBCenHTanXKeQMeta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphomaBMC Med201614277455505066288 LauJCheungJNavarroALianoglouSHaleyBTotpalKTumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceNat Commun201781:CAS:528:DC%2BC2sXjtlyisLo%3D282207725321797 Roda-NavarroPReyburnHTIntercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significanceFASEB J2007211636461:CAS:528:DC%2BD2sXmsVWlurc%3D17314139 YearleyJHGibsonCYuNMoonCMurphyEJucoJPD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancerClin Cancer Res2017233158671:CAS:528:DC%2BC2sXhtVSqurbL28619999 PeyraudFCousinSItalianoACSF-1R inhibitor development: current clinical statusCurr Oncol Rep20171928875266 CaderFZSchackmannRCJHuXWienandKReddRChapuyBMass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironmentBlood2018132825361:CAS:528:DC%2BC1cXhvFKqurrF298806156107878 WeinFKuppersRThe role of T cells in the microenvironment of Hodgkin lymphomaJ Leukoc Biol20169945501:CAS:528:DC%2BC28XovVequrg%3D26320264 OttPAHuZKeskinDBShuklaSASunJBozymDJAn immunogenic personal neoantigen vaccine for patients with melanomaNature2017547217211:CAS:528:DC%2BC2sXhtFaqt7rO286787785577644 ArmandPShippMARibragVMichotJMZinzaniPLKuruvillaJProgrammed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failureJ Clin Oncol201634373391:CAS:528:DC%2BC1cXhtV2htrg%3D273544765791838 WeinFWenigerMAHoingBArnoldsJHuttmannAHansmannMLComplex immune evasion strategies in classical Hodgkin lymphomaCancer Immunol Res201751122321:CAS:528:DC%2BC2sXhvFWhsbrF29070649 MaYVisserLRoelofsenHde VriesMDiepstraAvan ImhoffGProteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytesBlood20081112339461:CAS:528:DC%2BD1cXisVeitL0%3D18070985 ChenBJChapuyBOuyangJSunHHRoemerMGXuMLPD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignanciesClin Cancer Res2013193462731:CAS:528:DC%2BC3sXhtValt7nJ236744954102335 AldinucciDGloghiniAPintoADe FilippiRCarboneAThe classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escapeJ Pathol2010221248631:CAS:528:DC%2BC3cXptFymtLk%3D20527019 MimuraKTehJLOkayamaHShiraishiKKuaLFKohVPD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancerCancer Sci201810943531:CAS:528:DC%2BC2sXhvValurnK29034543 SwerdlowSHCampoEHarrisNJaffeESPileriSASteinHWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)2017LyonIARC TrambasCMGriffithsGMDelivering the kiss of deathNat Immunol200343994031:CAS:528:DC%2BD3sXjtlaktr4%3D12719728 CareyCDGusenleitnerDLipschitzMRoemerMGMStackECGjiniETopological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaBlood20171302420301:CAS:528:DC%2BC1cXhs1erurnK288937335766840 GreenMRMontiSRodigSJJuszczynskiPCurrieTO’DonnellEIntegrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood20101163268771:CAS:528:DC%2BC3cXhsVeisLjP206281452995356 HoWTPangWLChongSMCastellaAAl-SalamSTanTEExpression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expressionCancer Res2012736526123204227 TanakaYMaeshimaAMNomotoJMakitaSFukuharaSMunakataWExpression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphomaEur J Haematol201810051171:CAS:528:DC%2BC1cXotlCgu7o%3D29377256 DavisDMIntercellular transfer of cell-surface proteins is common and can affect many stages of an immune responseNat Rev Immunol20077238431:CAS:528:DC%2BD2sXitVGrtbs%3D17290299 ChenRZinzaniPLFanaleMAArmandPJohnsonNABricePPhase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphomaJ Clin Oncol2017352125321:CAS:528:DC%2BC1cXhvFKnsbrP284411115791843 RoemerMGAdvaniRHLigonAHNatkunamYReddRAHomerHPD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcomeJ Clin Oncol201634269071:CAS:528:DC%2BC28XitFelsL7K270690845019753 LinHWeiSHurtEMGreenMDZhaoLVatanLHost expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regressionJ Clin Investig201812880515293373055785251 Garcia-DiazAShinDSMorenoBHSacoJEscuin-OrdinasHRodriguezGAInterferon receptor signaling pathways regulating PD-L1 and PD-L2 expressionCell Rep20171911892011:CAS:528:DC%2BC2sXnsFeht7c%3D284948686420824 KuppersREngertAHansmannMLHodgkin lymphomaJ Clin Investig2012122343947230237153534167 HerbauxCGauthierJBricePDrumezEYsebaertLDoyenHEfficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaBlood2017129247181:CAS:528:DC%2BC2sXhtFyjsrbF28270452 ReichelJChadburnARubinsteinPGGiulino-RothLTamWLiuYFlow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Ster MGM Roemer (737_CR39) 2018; 36 KL Tan (737_CR6) 2012; 120 M Thorn (737_CR48) 2016; 23 R Chen (737_CR21) 2017; 35 D Aldinucci (737_CR2) 2010; 221 PA Ott (737_CR37) 2017; 547 Y Tanaka (737_CR52) 2018; 100 J Reichel (737_CR38) 2015; 125 Y Ma (737_CR11) 2008; 111 F Vari (737_CR28) 2018; 131 SM Ansell (737_CR18) 2015; 372 S Kreiter (737_CR35) 2015; 520 WT Ho (737_CR50) 2012; 73 CM Trambas (737_CR34) 2003; 4 MR Green (737_CR16) 2010; 116 BJ Chen (737_CR27) 2013; 19 ME Keir (737_CR45) 2008; 26 C Steidl (737_CR5) 2010; 362 CD Carey (737_CR14) 2017; 130 C Linnemann (737_CR36) 2015; 21 PC Tumeh (737_CR40) 2014; 515 DM Kuang (737_CR23) 2009; 206 P Armand (737_CR20) 2016; 34 A Garcia-Diaz (737_CR46) 2017; 19 A Younes (737_CR19) 2016; 17 KA Ahmed (737_CR30) 2008; 5 MG Roemer (737_CR17) 2016; 34 T Tadmor (737_CR8) 2015; 90 C Herbaux (737_CR22) 2017; 129 JH Yearley (737_CR26) 2017; 23 SH Swerdlow (737_CR1) 2017 DM Davis (737_CR29) 2007; 7 P Roda-Navarro (737_CR33) 2007; 21 B von Tresckow (737_CR13) 2015; 21 P Gu (737_CR49) 2012; 9 LF Porrata (737_CR9) 2012; 97 FZ Cader (737_CR44) 2018; 132 F Peyraud (737_CR12) 2017; 19 B Guo (737_CR7) 2016; 14 M Nakayama (737_CR32) 2011; 108 C Steidl (737_CR3) 2011; 29 R Kuppers (737_CR4) 2012; 122 R Yamamoto (737_CR15) 2008; 111 K Mimura (737_CR47) 2018; 109 N Casagrande (737_CR53) 2019; 104 SJ Im (737_CR41) 2016; 537 H Lin (737_CR25) 2018; 128 BF Skinnider (737_CR10) 2002; 99 F Wein (737_CR43) 2017; 5 J Lau (737_CR24) 2017; 8 M Nakayama (737_CR31) 2014; 5 F Wein (737_CR42) 2016; 99 PK Panjwani (737_CR51) 2018; 71 |
References_xml | – volume: 19 start-page: 1189 year: 2017 ident: 737_CR46 publication-title: Cell Rep doi: 10.1016/j.celrep.2017.04.031 contributor: fullname: A Garcia-Diaz – volume: 99 start-page: 45 year: 2016 ident: 737_CR42 publication-title: J Leukoc Biol doi: 10.1189/jlb.3MR0315-136R contributor: fullname: F Wein – volume: 99 start-page: 4283 year: 2002 ident: 737_CR10 publication-title: Blood doi: 10.1182/blood-2002-01-0099 contributor: fullname: BF Skinnider – volume: 21 start-page: 1843 year: 2015 ident: 737_CR13 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1845 contributor: fullname: B von Tresckow – volume: 71 start-page: 91 year: 2018 ident: 737_CR51 publication-title: Hum Pathol doi: 10.1016/j.humpath.2017.10.029 contributor: fullname: PK Panjwani – volume: 9 start-page: 136 year: 2012 ident: 737_CR49 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.62 contributor: fullname: P Gu – volume: 111 start-page: 3220 year: 2008 ident: 737_CR15 publication-title: Blood doi: 10.1182/blood-2007-05-085159 contributor: fullname: R Yamamoto – volume: 108 start-page: 18360 year: 2011 ident: 737_CR32 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1110584108 contributor: fullname: M Nakayama – volume: 122 start-page: 3439 year: 2012 ident: 737_CR4 publication-title: J Clin Investig doi: 10.1172/JCI61245 contributor: fullname: R Kuppers – volume: 5 start-page: 1122 year: 2017 ident: 737_CR43 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-17-0325 contributor: fullname: F Wein – volume: 520 start-page: 692 year: 2015 ident: 737_CR35 publication-title: Nature doi: 10.1038/nature14426 contributor: fullname: S Kreiter – volume: 128 start-page: 805 year: 2018 ident: 737_CR25 publication-title: J Clin Investig doi: 10.1172/JCI96113 contributor: fullname: H Lin – volume: 111 start-page: 2339 year: 2008 ident: 737_CR11 publication-title: Blood doi: 10.1182/blood-2007-09-112128 contributor: fullname: Y Ma – volume: 116 start-page: 3268 year: 2010 ident: 737_CR16 publication-title: Blood doi: 10.1182/blood-2010-05-282780 contributor: fullname: MR Green – volume: 362 start-page: 875 year: 2010 ident: 737_CR5 publication-title: N. Engl J Med doi: 10.1056/NEJMoa0905680 contributor: fullname: C Steidl – volume: 36 start-page: 942 year: 2018 ident: 737_CR39 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.3994 contributor: fullname: MGM Roemer – volume: 19 start-page: 3462 year: 2013 ident: 737_CR27 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0855 contributor: fullname: BJ Chen – volume: 5 start-page: 261 year: 2008 ident: 737_CR30 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2008.32 contributor: fullname: KA Ahmed – volume: 125 start-page: 1061 year: 2015 ident: 737_CR38 publication-title: Blood doi: 10.1182/blood-2014-11-610436 contributor: fullname: J Reichel – volume: 21 start-page: 81 year: 2015 ident: 737_CR36 publication-title: Nat Med doi: 10.1038/nm.3773 contributor: fullname: C Linnemann – volume: 29 start-page: 1812 year: 2011 ident: 737_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.32.8401 contributor: fullname: C Steidl – volume: 34 start-page: 2690 year: 2016 ident: 737_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.66.4482 contributor: fullname: MG Roemer – volume: 90 start-page: 756 year: 2015 ident: 737_CR8 publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2015.03.025 contributor: fullname: T Tadmor – volume: 4 start-page: 399 year: 2003 ident: 737_CR34 publication-title: Nat Immunol doi: 10.1038/ni0503-399 contributor: fullname: CM Trambas – volume: 23 start-page: 188 year: 2016 ident: 737_CR48 publication-title: Cancer Gene Ther doi: 10.1038/cgt.2016.19 contributor: fullname: M Thorn – volume-title: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition) year: 2017 ident: 737_CR1 contributor: fullname: SH Swerdlow – volume: 7 start-page: 238 year: 2007 ident: 737_CR29 publication-title: Nat Rev Immunol doi: 10.1038/nri2020 contributor: fullname: DM Davis – volume: 21 start-page: 1636 year: 2007 ident: 737_CR33 publication-title: FASEB J doi: 10.1096/fj.06-7488rev contributor: fullname: P Roda-Navarro – volume: 35 start-page: 2125 year: 2017 ident: 737_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.72.1316 contributor: fullname: R Chen – volume: 515 start-page: 568 year: 2014 ident: 737_CR40 publication-title: Nature doi: 10.1038/nature13954 contributor: fullname: PC Tumeh – volume: 8 year: 2017 ident: 737_CR24 publication-title: Nat Commun contributor: fullname: J Lau – volume: 73 start-page: 652 year: 2012 ident: 737_CR50 publication-title: Cancer Res contributor: fullname: WT Ho – volume: 17 start-page: 1283 year: 2016 ident: 737_CR19 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30167-X contributor: fullname: A Younes – volume: 129 start-page: 2471 year: 2017 ident: 737_CR22 publication-title: Blood doi: 10.1182/blood-2016-11-749556 contributor: fullname: C Herbaux – volume: 131 start-page: 1809 year: 2018 ident: 737_CR28 publication-title: Blood doi: 10.1182/blood-2017-07-796342 contributor: fullname: F Vari – volume: 537 start-page: 417 year: 2016 ident: 737_CR41 publication-title: Nature doi: 10.1038/nature19330 contributor: fullname: SJ Im – volume: 221 start-page: 248 year: 2010 ident: 737_CR2 publication-title: J Pathol doi: 10.1002/path.2711 contributor: fullname: D Aldinucci – volume: 100 start-page: 511 year: 2018 ident: 737_CR52 publication-title: Eur J Haematol doi: 10.1111/ejh.13033 contributor: fullname: Y Tanaka – volume: 97 start-page: 262 year: 2012 ident: 737_CR9 publication-title: Haematologica doi: 10.3324/haematol.2011.050138 contributor: fullname: LF Porrata – volume: 372 start-page: 311 year: 2015 ident: 737_CR18 publication-title: N. Engl J Med doi: 10.1056/NEJMoa1411087 contributor: fullname: SM Ansell – volume: 206 start-page: 1327 year: 2009 ident: 737_CR23 publication-title: J Exp Med doi: 10.1084/jem.20082173 contributor: fullname: DM Kuang – volume: 23 start-page: 3158 year: 2017 ident: 737_CR26 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1761 contributor: fullname: JH Yearley – volume: 14 year: 2016 ident: 737_CR7 publication-title: BMC Med contributor: fullname: B Guo – volume: 547 start-page: 217 year: 2017 ident: 737_CR37 publication-title: Nature doi: 10.1038/nature22991 contributor: fullname: PA Ott – volume: 132 start-page: 825 year: 2018 ident: 737_CR44 publication-title: Blood doi: 10.1182/blood-2018-04-843714 contributor: fullname: FZ Cader – volume: 109 start-page: 43 year: 2018 ident: 737_CR47 publication-title: Cancer Sci doi: 10.1111/cas.13424 contributor: fullname: K Mimura – volume: 120 start-page: 3280 year: 2012 ident: 737_CR6 publication-title: Blood doi: 10.1182/blood-2012-04-421057 contributor: fullname: KL Tan – volume: 130 start-page: 2420 year: 2017 ident: 737_CR14 publication-title: Blood doi: 10.1182/blood-2017-03-770719 contributor: fullname: CD Carey – volume: 19 year: 2017 ident: 737_CR12 publication-title: Curr Oncol Rep doi: 10.1007/s11912-017-0634-1 contributor: fullname: F Peyraud – volume: 34 start-page: 3733 year: 2016 ident: 737_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.67.3467 contributor: fullname: P Armand – volume: 104 start-page: 564 year: 2019 ident: 737_CR53 publication-title: Haematologica doi: 10.3324/haematol.2018.196725 contributor: fullname: N Casagrande – volume: 26 start-page: 677 year: 2008 ident: 737_CR45 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090331 contributor: fullname: ME Keir – volume: 5 start-page: 672 year: 2014 ident: 737_CR31 publication-title: Front Immunol contributor: fullname: M Nakayama |
SSID | ssj0014766 |
Score | 2.5220635 |
Snippet | In classical Hodgkin lymphoma (cHL)—characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells—tumor-associated macrophages (TAMs) play a pivotal... In classical Hodgkin lymphoma (cHL)-characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells-tumor-associated macrophages (TAMs) play a pivotal... In classical Hodgkin lymphoma (cHL)--characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells--tumor-associated macrophages (TAMs) play a... |
SourceID | proquest gale crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2405 |
SubjectTerms | 13/31 13/51 14/19 631/250/580 631/67/1990/291/1556 Analysis Antigen presentation Antigens B cells B7-H1 Antigen - metabolism Cancer Research CD4 antigen Cell Line, Tumor Cell Movement Critical Care Medicine Exhaustion Hematology Hodgkin Disease - immunology Hodgkin Disease - metabolism Hodgkin Disease - pathology Hodgkin's lymphoma Humans Immunofluorescence Intensive Internal Medicine Lymphocytes Lymphocytes T Lymphoma Macrophages Major histocompatibility complex Major Histocompatibility Complex - immunology Medicine Medicine & Public Health Monocytes Monocytes - metabolism Non-Hodgkin's lymphomas Oncology PD-1 protein PD-L1 protein Plasma membranes Programmed Cell Death 1 Ligand 2 Protein - metabolism T cells Tumor cells Tumor Microenvironment - immunology |
Title | PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma |
URI | https://link.springer.com/article/10.1038/s41375-020-0737-9 https://www.ncbi.nlm.nih.gov/pubmed/32089543 https://www.proquest.com/docview/2437278187 https://www.proquest.com/docview/2475018475 https://search.proquest.com/docview/2363070224 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED_WFMZexr7nrus0GAw2TGxLluSn0XUtYbSljBXyZmxLLmGtldlOIf_97vyRLYXuRWAkC-u-9LPudAfwIeM2zoURvtChxKbMfE1hYgWVWyXEHXQ1I8_O5exSfJ_H8-HArRnCKkeb2Blq4wo6I59GQlHuOWy_LH_7VDWKvKtDCY0d2I0oc9MEdr8en1_82PgRhOq9laRKEn81Rr8m19MGzbei28mBj2Ku_GRrZ7prn__ZoO54TLuN6OQJPB4QJDvsWf4UHtjqGTw8G3zkz2F18c0_DaenEetyMCwqdk2BQQ2rs-XCXK_ZoiKk2FjmKoarcsUa4Sa7XWSsrd0VPbpm0TC6eMLa1Y2rGZ3uN_geKwhrE1vZzJmrXzT3GsXB3WQv4PLk-OfRzB-KK_iFTGTrGxlKZfKkLK1RosgFN7GJdaEDg9SSouRGx0EZR7myEpXWII1sopNclzxKELi9hEnlKvsaGO5xOSKxyNpSCJGjWAQmozxmoY0lvunBp5Gw6bLPoZF2vm-u054LKXIhJS6kiQfviPRpfw10o3_poeRcSkpY5sHHbgRpYFtnRTZcJMCPoVxWWyP3t0ai5hTb3SN700Fzm5QSNEYKYYy6p3sUQw_eb7ppYgpWq6xb4RguyZIiOPLgVS81m3XzKNBJLLgHn0cx-jv5vUTZ-_-nvIFHUSfHFPq2D5O2Xtm3iJXa_AB21Fxhq4_Cg0E5_gCZiA8Q |
link.rule.ids | 315,786,790,12077,12244,21409,27946,27947,31743,31744,33290,33291,33768,33769,43334,43603,43829,74091,74360,74648 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0gvpS6ldNbe0KgqCES7Kb3c2TlNZy6l3xoYV7W5LspgTb7JnkhPvvncnH6RXqy0LYD5L52l92ZmcIeZ8yG2fccJ-rUEBTpL7CMLEcy60i4g66mpHzCzG94t8W8WI4cGuGsMrRJnaG2rgcz8gnEZeYew7az8tfPlaNQu_qUELjIXnEGWOYO18uNj9cIZe9rxIVScCPxujVZGrSgPGWeDc58EHIpZ9s7Ut3rfM_29Mdf2m3DZ3vkd0BP9KTnuHPyANbPSeP54OH_AVZ_TjzZ-FkFtEuA0NZ0RsMC2ponS5Lc7OmZYU4sbHUVRS-yeVrAJv0d5nStnbX-OiasqF47YS2q1tXUzzbb2AezRFpI1Pp1Jnrn7j2GoTB3aYvydX5l8vTqT-UVvBzkYjWNyIU0mRJUVgjeZ5xZmITq1wFBqgleMGMioMijjJpBaisARrZRCWZKliUAGx7RXYqV9nXhMIOlwEOi6wtOOcZCEVgUsxiFtpYwEyPfBwJq5d9Bg3deb6Z0j0XNHBBIxd04pFjJL3uL4FutE-fCMaEwHRlHvnQjUD9a-s0T4drBPAymMlqa-Th1kjQm3y7e2SvHvS20ZieMZIAYuQ93aMQeuTdphsXxlC1yroVjGEC7ShAI4_s91Kz-W4WBSqJOfPIp1GM_i5-L1EO_v8qx-TJ9HI-07OvF9_fkKdRJ9MYBHdIdtp6ZY8ANbXZ2041_gAimw7h |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEB-0QvFF_G5qtSsIghIul91sNk9SWo9Tr6UPFvq2JNlNCbbZa5IT7r93Jh-nV6gvgbCbJTufv2RmZwA-pNxGmTDCF2oq8VKkvqI0sZzarRLiDrqekadncn4hvl9Gl0P-UzOkVY42sTPUxuX0j3wSiphqz-F1UgxpEecnsy_LW586SFGkdWin8RAeoVeU1MZBHW_SPaYi7uOWpFQSPzrGCCdXkwYNeUznlAMfBT72ky0fdddS_-Oq7sROO5c0ewpPBizJjnrmP4MHtnoOu6dDtPwFrM5P_MV0sghZV42hrNg1pQg1rE6Xpbles7IizNhY5iqGe3L5GoEn-12mrK3dFd26pmwYHUFh7erG1Yz-8zf4HMsJdROD2dyZq1-09hoFw92kL-Fi9vXn8dwf2iz4uUxk6xs5lbHJkqKwJhZ5JriJTKRyFRiklhQFNyoKiijMYitRfQ3SyCYqyVTBwwQh3CvYqVxl94Cht8sQk4XWFkKIDAUkMClVNJvaSOKTHnwaCauXfTUN3UXBudI9FzRyQRMXdOLBIZFe9wdCN5qojyTnUlLpMg8-djNIF9s6zdPhSAG-DFW12pp5sDUTdSjfHh7ZqwcdbjSVagxjBDTxPcOjQHrwfjNMC1PaWmXdCudwSTYVYZIHr3up2eybh4FKIsE9-DyK0d_F7yXK_v9f5RB2USv04tvZjzfwOOxEmvLhDmCnrVf2LQKoNnvXacYf2T4S4Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PD-L1%2FL2+protein+levels+rapidly+increase+on+monocytes+via+trogocytosis+from+tumor+cells+in+classical+Hodgkin+lymphoma&rft.jtitle=Leukemia&rft.au=Kawashima%2C+Masaharu&rft.au=Carreras%2C+Joaquim&rft.au=Higuchi%2C+Hiroshi&rft.au=Kotaki%2C+Ryutaro&rft.date=2020-09-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=0887-6924&rft.eissn=1476-5551&rft.volume=34&rft.issue=9&rft.spage=2405&rft.epage=2417&rft_id=info:doi/10.1038%2Fs41375-020-0737-9&rft.externalDocID=10_1038_s41375_020_0737_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-6924&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-6924&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-6924&client=summon |